2024-04-18 13:26:18 ET
Summary
- ALX Oncology's main focus is the CD47 blocker evorpacept, which has shown encouraging results in combination with other therapies for various cancers.
- The company has a strong financial position with enough runway to fund operations into early 2026.
- There is both potential and risk associated with evorpacept, as it has shown positive early data but nothing convincing, so the long-term outlook is very unclear.
Top-Line Summary and Update
Read the full article on Seeking Alpha
For further details see:
ALX Oncology: Trying To Justify The Hype